nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisuride—DRD5—eyelid—head and neck cancer	0.102	0.237	CbGeAlD
Lisuride—CYP2D6—Hydroxyurea—head and neck cancer	0.0694	0.567	CbGbCtD
Lisuride—HTR1B—trigeminal nerve—head and neck cancer	0.0459	0.107	CbGeAlD
Lisuride—HTR1D—trigeminal nerve—head and neck cancer	0.0444	0.104	CbGeAlD
Lisuride—HTR1B—cranial nerve—head and neck cancer	0.0327	0.0763	CbGeAlD
Lisuride—HTR1D—cranial nerve—head and neck cancer	0.0317	0.0739	CbGeAlD
Lisuride—CYP2D6—Vinblastine—head and neck cancer	0.0246	0.201	CbGbCtD
Lisuride—HTR2A—trigeminal nerve—head and neck cancer	0.0221	0.0515	CbGeAlD
Lisuride—Pulmonary fibrosis—Hydroxyurea—head and neck cancer	0.0212	0.0842	CcSEcCtD
Lisuride—HTR2A—cranial nerve—head and neck cancer	0.0157	0.0367	CbGeAlD
Lisuride—CYP3A4—Vinblastine—head and neck cancer	0.0156	0.128	CbGbCtD
Lisuride—Pericarditis—Fluorouracil—head and neck cancer	0.0155	0.0616	CcSEcCtD
Lisuride—CYP3A4—Docetaxel—head and neck cancer	0.0129	0.105	CbGbCtD
Lisuride—Pericardial effusion—Docetaxel—head and neck cancer	0.0118	0.0469	CcSEcCtD
Lisuride—Pulmonary fibrosis—Docetaxel—head and neck cancer	0.011	0.0437	CcSEcCtD
Lisuride—ADRA1D—epithelium—head and neck cancer	0.0083	0.0194	CbGeAlD
Lisuride—DRD5—lymphoid tissue—head and neck cancer	0.00797	0.0186	CbGeAlD
Lisuride—Disorientation—Hydroxyurea—head and neck cancer	0.00755	0.03	CcSEcCtD
Lisuride—DRD3—head—head and neck cancer	0.00685	0.016	CbGeAlD
Lisuride—HTR1D—connective tissue—head and neck cancer	0.00654	0.0153	CbGeAlD
Lisuride—DRD5—head—head and neck cancer	0.00642	0.015	CbGeAlD
Lisuride—ADRB1—connective tissue—head and neck cancer	0.00635	0.0148	CbGeAlD
Lisuride—Pleural effusion—Docetaxel—head and neck cancer	0.00631	0.0251	CcSEcCtD
Lisuride—ADRA2C—parotid gland—head and neck cancer	0.00544	0.0127	CbGeAlD
Lisuride—Disorientation—Fluorouracil—head and neck cancer	0.00543	0.0216	CcSEcCtD
Lisuride—Weight increased—Hydroxyurea—head and neck cancer	0.00531	0.0211	CcSEcCtD
Lisuride—ADRA1B—head—head and neck cancer	0.00527	0.0123	CbGeAlD
Lisuride—ADRA1D—head—head and neck cancer	0.00515	0.012	CbGeAlD
Lisuride—DRD1—head—head and neck cancer	0.00491	0.0115	CbGeAlD
Lisuride—Blood pressure increased—Docetaxel—head and neck cancer	0.00483	0.0192	CcSEcCtD
Lisuride—Hallucination—Hydroxyurea—head and neck cancer	0.00465	0.0185	CcSEcCtD
Lisuride—HTR2A—neck—head and neck cancer	0.00453	0.0106	CbGeAlD
Lisuride—Angiopathy—Hydroxyurea—head and neck cancer	0.00424	0.0169	CcSEcCtD
Lisuride—HTR2B—thyroid gland—head and neck cancer	0.00404	0.00942	CbGeAlD
Lisuride—ADRA2C—trachea—head and neck cancer	0.00402	0.00937	CbGeAlD
Lisuride—Vertigo—Vinblastine—head and neck cancer	0.00401	0.0159	CcSEcCtD
Lisuride—HTR1B—head—head and neck cancer	0.00398	0.00928	CbGeAlD
Lisuride—HTR1D—head—head and neck cancer	0.00385	0.00899	CbGeAlD
Lisuride—ADRA2A—connective tissue—head and neck cancer	0.00382	0.00891	CbGeAlD
Lisuride—HTR2C—head—head and neck cancer	0.00381	0.0089	CbGeAlD
Lisuride—ADRB1—head—head and neck cancer	0.00374	0.00873	CbGeAlD
Lisuride—HTR2B—head—head and neck cancer	0.00358	0.00836	CbGeAlD
Lisuride—Anorexia—Vinblastine—head and neck cancer	0.00347	0.0138	CcSEcCtD
Lisuride—Infection—Hydroxyurea—head and neck cancer	0.0033	0.0131	CcSEcCtD
Lisuride—Dehydration—Docetaxel—head and neck cancer	0.00326	0.013	CcSEcCtD
Lisuride—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00326	0.013	CcSEcCtD
Lisuride—HTR2A—connective tissue—head and neck cancer	0.00325	0.00758	CbGeAlD
Lisuride—HTR1A—head—head and neck cancer	0.00321	0.00749	CbGeAlD
Lisuride—ADRA2A—trachea—head and neck cancer	0.00321	0.00748	CbGeAlD
Lisuride—Orthostatic hypotension—Docetaxel—head and neck cancer	0.0032	0.0127	CcSEcCtD
Lisuride—Anorexia—Hydroxyurea—head and neck cancer	0.00316	0.0126	CcSEcCtD
Lisuride—Decreased appetite—Vinblastine—head and neck cancer	0.00316	0.0126	CcSEcCtD
Lisuride—Constipation—Vinblastine—head and neck cancer	0.00311	0.0124	CcSEcCtD
Lisuride—HTR2A—epithelium—head and neck cancer	0.00308	0.00719	CbGeAlD
Lisuride—Feeling abnormal—Vinblastine—head and neck cancer	0.003	0.0119	CcSEcCtD
Lisuride—Dyspnoea—Hydroxyurea—head and neck cancer	0.00296	0.0118	CcSEcCtD
Lisuride—Somnolence—Hydroxyurea—head and neck cancer	0.00295	0.0117	CcSEcCtD
Lisuride—DRD2—head—head and neck cancer	0.0029	0.00677	CbGeAlD
Lisuride—Decreased appetite—Hydroxyurea—head and neck cancer	0.00289	0.0115	CcSEcCtD
Lisuride—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00287	0.0114	CcSEcCtD
Lisuride—Fatigue—Hydroxyurea—head and neck cancer	0.00286	0.0114	CcSEcCtD
Lisuride—Constipation—Hydroxyurea—head and neck cancer	0.00284	0.0113	CcSEcCtD
Lisuride—ADRA2C—head—head and neck cancer	0.00282	0.00658	CbGeAlD
Lisuride—Weight increased—Docetaxel—head and neck cancer	0.00276	0.011	CcSEcCtD
Lisuride—Weight decreased—Docetaxel—head and neck cancer	0.00274	0.0109	CcSEcCtD
Lisuride—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00274	0.0109	CcSEcCtD
Lisuride—HTR2A—trachea—head and neck cancer	0.00273	0.00636	CbGeAlD
Lisuride—Asthenia—Vinblastine—head and neck cancer	0.00261	0.0104	CcSEcCtD
Lisuride—ADRA2A—thyroid gland—head and neck cancer	0.00254	0.00592	CbGeAlD
Lisuride—HTR2B—lymph node—head and neck cancer	0.00251	0.00585	CbGeAlD
Lisuride—Confusional state—Fluorouracil—head and neck cancer	0.00241	0.00958	CcSEcCtD
Lisuride—Dizziness—Vinblastine—head and neck cancer	0.00241	0.00958	CcSEcCtD
Lisuride—Oedema peripheral—Docetaxel—head and neck cancer	0.00239	0.00951	CcSEcCtD
Lisuride—Asthenia—Hydroxyurea—head and neck cancer	0.00238	0.00947	CcSEcCtD
Lisuride—Infection—Fluorouracil—head and neck cancer	0.00237	0.00944	CcSEcCtD
Lisuride—Nervous system disorder—Fluorouracil—head and neck cancer	0.00234	0.00932	CcSEcCtD
Lisuride—Tachycardia—Fluorouracil—head and neck cancer	0.00233	0.00928	CcSEcCtD
Lisuride—Vomiting—Vinblastine—head and neck cancer	0.00231	0.00921	CcSEcCtD
Lisuride—Headache—Vinblastine—head and neck cancer	0.00228	0.00907	CcSEcCtD
Lisuride—Anorexia—Fluorouracil—head and neck cancer	0.00228	0.00906	CcSEcCtD
Lisuride—Cardiac disorder—Docetaxel—head and neck cancer	0.00225	0.00896	CcSEcCtD
Lisuride—ADRA2A—head—head and neck cancer	0.00225	0.00525	CbGeAlD
Lisuride—Angiopathy—Docetaxel—head and neck cancer	0.0022	0.00876	CcSEcCtD
Lisuride—Dizziness—Hydroxyurea—head and neck cancer	0.00219	0.00873	CcSEcCtD
Lisuride—Immune system disorder—Docetaxel—head and neck cancer	0.00219	0.00872	CcSEcCtD
Lisuride—Mediastinal disorder—Docetaxel—head and neck cancer	0.00219	0.0087	CcSEcCtD
Lisuride—Insomnia—Fluorouracil—head and neck cancer	0.00216	0.0086	CcSEcCtD
Lisuride—Dyspnoea—Fluorouracil—head and neck cancer	0.00213	0.00847	CcSEcCtD
Lisuride—Mental disorder—Docetaxel—head and neck cancer	0.00213	0.00846	CcSEcCtD
Lisuride—Somnolence—Fluorouracil—head and neck cancer	0.00212	0.00845	CcSEcCtD
Lisuride—Malnutrition—Docetaxel—head and neck cancer	0.00211	0.00841	CcSEcCtD
Lisuride—Vomiting—Hydroxyurea—head and neck cancer	0.00211	0.0084	CcSEcCtD
Lisuride—Headache—Hydroxyurea—head and neck cancer	0.00208	0.00827	CcSEcCtD
Lisuride—Decreased appetite—Fluorouracil—head and neck cancer	0.00208	0.00826	CcSEcCtD
Lisuride—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00206	0.00821	CcSEcCtD
Lisuride—ADRA2C—lymph node—head and neck cancer	0.00197	0.00461	CbGeAlD
Lisuride—Feeling abnormal—Fluorouracil—head and neck cancer	0.00197	0.00783	CcSEcCtD
Lisuride—HTR2A—head—head and neck cancer	0.00191	0.00446	CbGeAlD
Lisuride—Syncope—Docetaxel—head and neck cancer	0.00189	0.00754	CcSEcCtD
Lisuride—Palpitations—Docetaxel—head and neck cancer	0.00187	0.00743	CcSEcCtD
Lisuride—Cough—Docetaxel—head and neck cancer	0.00184	0.00734	CcSEcCtD
Lisuride—Dry mouth—Docetaxel—head and neck cancer	0.00176	0.007	CcSEcCtD
Lisuride—CYP2D6—head—head and neck cancer	0.00174	0.00407	CbGeAlD
Lisuride—Confusional state—Docetaxel—head and neck cancer	0.00174	0.00692	CcSEcCtD
Lisuride—Infection—Docetaxel—head and neck cancer	0.00171	0.00682	CcSEcCtD
Lisuride—Nervous system disorder—Docetaxel—head and neck cancer	0.00169	0.00673	CcSEcCtD
Lisuride—Tachycardia—Docetaxel—head and neck cancer	0.00168	0.0067	CcSEcCtD
Lisuride—Anorexia—Docetaxel—head and neck cancer	0.00164	0.00654	CcSEcCtD
Lisuride—Dizziness—Fluorouracil—head and neck cancer	0.00158	0.00629	CcSEcCtD
Lisuride—ADRA2A—lymph node—head and neck cancer	0.00158	0.00368	CbGeAlD
Lisuride—Insomnia—Docetaxel—head and neck cancer	0.00156	0.00621	CcSEcCtD
Lisuride—Dyspnoea—Docetaxel—head and neck cancer	0.00154	0.00612	CcSEcCtD
Lisuride—Somnolence—Docetaxel—head and neck cancer	0.00153	0.0061	CcSEcCtD
Lisuride—Vomiting—Fluorouracil—head and neck cancer	0.00152	0.00604	CcSEcCtD
Lisuride—Decreased appetite—Docetaxel—head and neck cancer	0.0015	0.00596	CcSEcCtD
Lisuride—Headache—Fluorouracil—head and neck cancer	0.0015	0.00595	CcSEcCtD
Lisuride—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.00149	0.00592	CcSEcCtD
Lisuride—Fatigue—Docetaxel—head and neck cancer	0.00149	0.00591	CcSEcCtD
Lisuride—Constipation—Docetaxel—head and neck cancer	0.00147	0.00587	CcSEcCtD
Lisuride—Feeling abnormal—Docetaxel—head and neck cancer	0.00142	0.00565	CcSEcCtD
Lisuride—Asthenia—Docetaxel—head and neck cancer	0.00124	0.00492	CcSEcCtD
Lisuride—Dizziness—Docetaxel—head and neck cancer	0.00114	0.00454	CcSEcCtD
Lisuride—Vomiting—Docetaxel—head and neck cancer	0.0011	0.00436	CcSEcCtD
Lisuride—Headache—Docetaxel—head and neck cancer	0.00108	0.0043	CcSEcCtD
Lisuride—ADRA2A—Signaling Pathways—NOTCH1—head and neck cancer	4.7e-05	0.000237	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—VEGFA—head and neck cancer	4.68e-05	0.000237	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—MAPK1—head and neck cancer	4.67e-05	0.000236	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—EGFR—head and neck cancer	4.67e-05	0.000236	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—CCND1—head and neck cancer	4.66e-05	0.000236	CbGpPWpGaD
Lisuride—HTR2B—Signaling by GPCR—AKT1—head and neck cancer	4.65e-05	0.000235	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—STAT3—head and neck cancer	4.64e-05	0.000235	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—TP53—head and neck cancer	4.62e-05	0.000234	CbGpPWpGaD
Lisuride—HTR1A—Signaling by GPCR—PIK3CA—head and neck cancer	4.62e-05	0.000234	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—GPX1—head and neck cancer	4.62e-05	0.000233	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—MAPK1—head and neck cancer	4.6e-05	0.000233	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—CCND1—head and neck cancer	4.6e-05	0.000233	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—CCND1—head and neck cancer	4.6e-05	0.000233	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—EGFR—head and neck cancer	4.6e-05	0.000233	CbGpPWpGaD
Lisuride—HTR2C—Signaling by GPCR—PIK3CA—head and neck cancer	4.6e-05	0.000232	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—VEGFA—head and neck cancer	4.59e-05	0.000232	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—CYP1A1—head and neck cancer	4.57e-05	0.000231	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—STAT3—head and neck cancer	4.54e-05	0.00023	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—VEGFA—head and neck cancer	4.51e-05	0.000228	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—PTEN—head and neck cancer	4.5e-05	0.000228	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—PTEN—head and neck cancer	4.48e-05	0.000226	CbGpPWpGaD
Lisuride—ADRA2C—Signaling by GPCR—PIK3CA—head and neck cancer	4.47e-05	0.000226	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—STAT3—head and neck cancer	4.47e-05	0.000226	CbGpPWpGaD
Lisuride—ADRB1—Signaling by GPCR—HRAS—head and neck cancer	4.47e-05	0.000226	CbGpPWpGaD
Lisuride—DRD2—GPCR downstream signaling—PIK3CA—head and neck cancer	4.47e-05	0.000226	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—PTEN—head and neck cancer	4.44e-05	0.000224	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—PTEN—head and neck cancer	4.44e-05	0.000224	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—MAPK3—head and neck cancer	4.43e-05	0.000224	CbGpPWpGaD
Lisuride—ADRA2B—Signaling by GPCR—HRAS—head and neck cancer	4.43e-05	0.000224	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—HRAS—head and neck cancer	4.42e-05	0.000223	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—PIK3CA—head and neck cancer	4.4e-05	0.000223	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—MAPK3—head and neck cancer	4.4e-05	0.000222	CbGpPWpGaD
Lisuride—HTR2A—GPCR downstream signaling—PIK3CA—head and neck cancer	4.39e-05	0.000222	CbGpPWpGaD
Lisuride—DRD1—Signaling by GPCR—AKT1—head and neck cancer	4.39e-05	0.000222	CbGpPWpGaD
Lisuride—ADRB1—GPCR downstream signaling—AKT1—head and neck cancer	4.34e-05	0.00022	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—MAPK3—head and neck cancer	4.34e-05	0.000219	CbGpPWpGaD
Lisuride—ADRA1D—Signaling by GPCR—AKT1—head and neck cancer	4.33e-05	0.000219	CbGpPWpGaD
Lisuride—DRD3—Signaling by GPCR—AKT1—head and neck cancer	4.33e-05	0.000219	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—VEGFA—head and neck cancer	4.31e-05	0.000218	CbGpPWpGaD
Lisuride—ADRA2B—GPCR downstream signaling—AKT1—head and neck cancer	4.31e-05	0.000218	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—IL2—head and neck cancer	4.3e-05	0.000217	CbGpPWpGaD
Lisuride—HTR1A—Signaling by GPCR—HRAS—head and neck cancer	4.27e-05	0.000216	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—MAPK3—head and neck cancer	4.27e-05	0.000216	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—STAT3—head and neck cancer	4.27e-05	0.000216	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—IL2—head and neck cancer	4.26e-05	0.000215	CbGpPWpGaD
Lisuride—HTR2C—Signaling by GPCR—HRAS—head and neck cancer	4.25e-05	0.000215	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—MAPK1—head and neck cancer	4.22e-05	0.000213	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—EGFR—head and neck cancer	4.22e-05	0.000213	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—CCND1—head and neck cancer	4.19e-05	0.000212	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—MAPK1—head and neck cancer	4.18e-05	0.000212	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—EGFR—head and neck cancer	4.18e-05	0.000212	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PTGS2—head and neck cancer	4.17e-05	0.000211	CbGpPWpGaD
Lisuride—HTR1A—GPCR downstream signaling—AKT1—head and neck cancer	4.16e-05	0.00021	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—CCND1—head and neck cancer	4.15e-05	0.00021	CbGpPWpGaD
Lisuride—ADRA2C—Signaling by GPCR—HRAS—head and neck cancer	4.14e-05	0.000209	CbGpPWpGaD
Lisuride—HTR2C—GPCR downstream signaling—AKT1—head and neck cancer	4.13e-05	0.000209	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—MAPK1—head and neck cancer	4.13e-05	0.000209	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—EGFR—head and neck cancer	4.13e-05	0.000209	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—IL2—head and neck cancer	4.11e-05	0.000208	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—IL2—head and neck cancer	4.09e-05	0.000207	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—MAPK3—head and neck cancer	4.08e-05	0.000206	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—HRAS—head and neck cancer	4.07e-05	0.000206	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—VEGFA—head and neck cancer	4.06e-05	0.000206	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—MAPK1—head and neck cancer	4.06e-05	0.000205	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—EGFR—head and neck cancer	4.06e-05	0.000205	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—PIK3CA—head and neck cancer	4.06e-05	0.000205	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—PTEN—head and neck cancer	4.04e-05	0.000205	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—STAT3—head and neck cancer	4.02e-05	0.000203	CbGpPWpGaD
Lisuride—ADRA2C—GPCR downstream signaling—AKT1—head and neck cancer	4.02e-05	0.000203	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—VEGFA—head and neck cancer	4.01e-05	0.000203	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—VEGFA—head and neck cancer	4.01e-05	0.000203	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—CCND1—head and neck cancer	4.01e-05	0.000203	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—PTEN—head and neck cancer	4.01e-05	0.000203	CbGpPWpGaD
Lisuride—ADRA2A—GPCR downstream signaling—PIK3CA—head and neck cancer	4e-05	0.000202	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—PIK3CA—head and neck cancer	3.99e-05	0.000202	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—CCND1—head and neck cancer	3.99e-05	0.000202	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—IL2—head and neck cancer	3.98e-05	0.000201	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—STAT3—head and neck cancer	3.97e-05	0.000201	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—STAT3—head and neck cancer	3.97e-05	0.000201	CbGpPWpGaD
Lisuride—ADRA1B—GPCR downstream signaling—AKT1—head and neck cancer	3.96e-05	0.0002	CbGpPWpGaD
Lisuride—ADRB1—Signaling by GPCR—AKT1—head and neck cancer	3.95e-05	0.0002	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—IL2—head and neck cancer	3.92e-05	0.000198	CbGpPWpGaD
Lisuride—ADRA2B—Signaling by GPCR—AKT1—head and neck cancer	3.91e-05	0.000198	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—AKT1—head and neck cancer	3.9e-05	0.000197	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—MAPK1—head and neck cancer	3.88e-05	0.000196	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—CCND1—head and neck cancer	3.88e-05	0.000196	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—EGFR—head and neck cancer	3.88e-05	0.000196	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—PTEN—head and neck cancer	3.87e-05	0.000196	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—PTEN—head and neck cancer	3.85e-05	0.000195	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—MAPK3—head and neck cancer	3.84e-05	0.000194	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—CCND1—head and neck cancer	3.82e-05	0.000193	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—MAPK3—head and neck cancer	3.79e-05	0.000192	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—MAPK3—head and neck cancer	3.79e-05	0.000192	CbGpPWpGaD
Lisuride—HTR1A—Signaling by GPCR—AKT1—head and neck cancer	3.77e-05	0.000191	CbGpPWpGaD
Lisuride—HTR2C—Signaling by GPCR—AKT1—head and neck cancer	3.75e-05	0.00019	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—HRAS—head and neck cancer	3.75e-05	0.00019	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—PTEN—head and neck cancer	3.74e-05	0.000189	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—HRAS—head and neck cancer	3.69e-05	0.000187	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—PTEN—head and neck cancer	3.68e-05	0.000186	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—PIK3CA—head and neck cancer	3.66e-05	0.000185	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—MAPK1—head and neck cancer	3.66e-05	0.000185	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—EGFR—head and neck cancer	3.66e-05	0.000185	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—VEGFA—head and neck cancer	3.65e-05	0.000185	CbGpPWpGaD
Lisuride—ADRA2C—Signaling by GPCR—AKT1—head and neck cancer	3.65e-05	0.000185	CbGpPWpGaD
Lisuride—DRD2—GPCR downstream signaling—AKT1—head and neck cancer	3.65e-05	0.000185	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PTEN—head and neck cancer	3.64e-05	0.000184	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—PIK3CA—head and neck cancer	3.63e-05	0.000184	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—VEGFA—head and neck cancer	3.62e-05	0.000183	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—STAT3—head and neck cancer	3.62e-05	0.000183	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—IL2—head and neck cancer	3.61e-05	0.000183	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—MAPK1—head and neck cancer	3.61e-05	0.000183	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—MAPK1—head and neck cancer	3.61e-05	0.000183	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—EGFR—head and neck cancer	3.61e-05	0.000182	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—EGFR—head and neck cancer	3.61e-05	0.000182	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—AKT1—head and neck cancer	3.59e-05	0.000182	CbGpPWpGaD
Lisuride—HTR2A—GPCR downstream signaling—AKT1—head and neck cancer	3.59e-05	0.000182	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—STAT3—head and neck cancer	3.58e-05	0.000181	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—PIK3CA—head and neck cancer	3.58e-05	0.000181	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—IL2—head and neck cancer	3.55e-05	0.00018	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—TP53—head and neck cancer	3.54e-05	0.000179	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—PIK3CA—head and neck cancer	3.53e-05	0.000178	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CCND1—head and neck cancer	3.52e-05	0.000178	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—VEGFA—head and neck cancer	3.49e-05	0.000177	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—VEGFA—head and neck cancer	3.48e-05	0.000176	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—TP53—head and neck cancer	3.47e-05	0.000175	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CCND1—head and neck cancer	3.46e-05	0.000175	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—STAT3—head and neck cancer	3.46e-05	0.000175	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MAPK3—head and neck cancer	3.46e-05	0.000175	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—STAT3—head and neck cancer	3.44e-05	0.000174	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MAPK3—head and neck cancer	3.42e-05	0.000173	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—TP53—head and neck cancer	3.41e-05	0.000172	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—PTEN—head and neck cancer	3.4e-05	0.000172	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—HRAS—head and neck cancer	3.38e-05	0.000171	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—VEGFA—head and neck cancer	3.38e-05	0.000171	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—PIK3CA—head and neck cancer	3.37e-05	0.00017	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—HRAS—head and neck cancer	3.36e-05	0.00017	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—STAT3—head and neck cancer	3.35e-05	0.000169	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PTEN—head and neck cancer	3.34e-05	0.000169	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—VEGFA—head and neck cancer	3.33e-05	0.000168	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—HRAS—head and neck cancer	3.31e-05	0.000168	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—AKT1—head and neck cancer	3.31e-05	0.000168	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MAPK3—head and neck cancer	3.31e-05	0.000167	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—STAT3—head and neck cancer	3.29e-05	0.000167	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MAPK3—head and neck cancer	3.29e-05	0.000166	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MAPK1—head and neck cancer	3.29e-05	0.000166	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—EGFR—head and neck cancer	3.29e-05	0.000166	CbGpPWpGaD
Lisuride—ADRA2A—GPCR downstream signaling—AKT1—head and neck cancer	3.27e-05	0.000165	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—HRAS—head and neck cancer	3.26e-05	0.000165	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—AKT1—head and neck cancer	3.26e-05	0.000165	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MAPK1—head and neck cancer	3.26e-05	0.000165	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—EGFR—head and neck cancer	3.26e-05	0.000165	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—TP53—head and neck cancer	3.26e-05	0.000165	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—IL2—head and neck cancer	3.23e-05	0.000163	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MAPK3—head and neck cancer	3.2e-05	0.000162	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—TYMS—head and neck cancer	3.19e-05	0.000161	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—PIK3CA—head and neck cancer	3.17e-05	0.000161	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—PIK3CA—head and neck cancer	3.16e-05	0.00016	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—GSTM1—head and neck cancer	3.15e-05	0.000159	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CCND1—head and neck cancer	3.15e-05	0.000159	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MAPK3—head and neck cancer	3.15e-05	0.000159	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MAPK1—head and neck cancer	3.14e-05	0.000159	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—EGFR—head and neck cancer	3.14e-05	0.000159	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—PIK3CA—head and neck cancer	3.13e-05	0.000158	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—PIK3CA—head and neck cancer	3.13e-05	0.000158	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MAPK1—head and neck cancer	3.13e-05	0.000158	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—EGFR—head and neck cancer	3.13e-05	0.000158	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—HRAS—head and neck cancer	3.11e-05	0.000157	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—TP53—head and neck cancer	3.07e-05	0.000155	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—VEGFA—head and neck cancer	3.07e-05	0.000155	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MAPK1—head and neck cancer	3.04e-05	0.000154	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—EGFR—head and neck cancer	3.04e-05	0.000154	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PTEN—head and neck cancer	3.04e-05	0.000154	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—STAT3—head and neck cancer	3.04e-05	0.000154	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—TP53—head and neck cancer	3.03e-05	0.000153	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—TP53—head and neck cancer	3.03e-05	0.000153	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—VEGFA—head and neck cancer	3.02e-05	0.000153	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—GPX1—head and neck cancer	3.02e-05	0.000153	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MAPK1—head and neck cancer	3e-05	0.000151	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—EGFR—head and neck cancer	2.99e-05	0.000151	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—AKT1—head and neck cancer	2.99e-05	0.000151	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—STAT3—head and neck cancer	2.99e-05	0.000151	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—CYP1A1—head and neck cancer	2.99e-05	0.000151	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—AKT1—head and neck cancer	2.97e-05	0.00015	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—HRAS—head and neck cancer	2.94e-05	0.000148	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—AKT1—head and neck cancer	2.93e-05	0.000148	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MAPK3—head and neck cancer	2.9e-05	0.000147	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—HRAS—head and neck cancer	2.9e-05	0.000147	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—HRAS—head and neck cancer	2.9e-05	0.000147	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—AKT1—head and neck cancer	2.88e-05	0.000146	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MAPK3—head and neck cancer	2.86e-05	0.000144	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—PIK3CA—head and neck cancer	2.85e-05	0.000144	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—PIK3CA—head and neck cancer	2.83e-05	0.000143	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MAPK1—head and neck cancer	2.76e-05	0.00014	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—EGFR—head and neck cancer	2.76e-05	0.00014	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—TP53—head and neck cancer	2.76e-05	0.00014	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—AKT1—head and neck cancer	2.75e-05	0.000139	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—VEGFA—head and neck cancer	2.75e-05	0.000139	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—TP53—head and neck cancer	2.73e-05	0.000138	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—PIK3CA—head and neck cancer	2.73e-05	0.000138	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—STAT3—head and neck cancer	2.72e-05	0.000138	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MAPK1—head and neck cancer	2.72e-05	0.000137	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PTGS2—head and neck cancer	2.72e-05	0.000137	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—EGFR—head and neck cancer	2.72e-05	0.000137	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—PIK3CA—head and neck cancer	2.71e-05	0.000137	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—PIK3CA—head and neck cancer	2.64e-05	0.000134	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—TP53—head and neck cancer	2.64e-05	0.000134	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—HRAS—head and neck cancer	2.64e-05	0.000134	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—TP53—head and neck cancer	2.63e-05	0.000133	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—HRAS—head and neck cancer	2.62e-05	0.000132	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—PIK3CA—head and neck cancer	2.6e-05	0.000131	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MAPK3—head and neck cancer	2.6e-05	0.000131	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—AKT1—head and neck cancer	2.59e-05	0.000131	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—AKT1—head and neck cancer	2.58e-05	0.00013	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PIK3CA—head and neck cancer	2.57e-05	0.00013	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—AKT1—head and neck cancer	2.56e-05	0.000129	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—AKT1—head and neck cancer	2.56e-05	0.000129	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—TP53—head and neck cancer	2.55e-05	0.000129	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—HRAS—head and neck cancer	2.52e-05	0.000128	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—TP53—head and neck cancer	2.51e-05	0.000127	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—HRAS—head and neck cancer	2.51e-05	0.000127	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MAPK1—head and neck cancer	2.47e-05	0.000125	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—EGFR—head and neck cancer	2.47e-05	0.000125	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—HRAS—head and neck cancer	2.44e-05	0.000124	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—HRAS—head and neck cancer	2.4e-05	0.000122	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—PIK3CA—head and neck cancer	2.4e-05	0.000121	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PTEN—head and neck cancer	2.37e-05	0.00012	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PIK3CA—head and neck cancer	2.36e-05	0.000119	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—AKT1—head and neck cancer	2.33e-05	0.000118	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—TP53—head and neck cancer	2.32e-05	0.000117	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—AKT1—head and neck cancer	2.31e-05	0.000117	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—TP53—head and neck cancer	2.28e-05	0.000115	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—AKT1—head and neck cancer	2.23e-05	0.000113	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—AKT1—head and neck cancer	2.22e-05	0.000112	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—HRAS—head and neck cancer	2.22e-05	0.000112	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—HRAS—head and neck cancer	2.18e-05	0.00011	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—AKT1—head and neck cancer	2.16e-05	0.000109	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PIK3CA—head and neck cancer	2.14e-05	0.000108	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—AKT1—head and neck cancer	2.12e-05	0.000107	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—AKT1—head and neck cancer	2.1e-05	0.000106	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—TP53—head and neck cancer	2.08e-05	0.000105	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—HRAS—head and neck cancer	1.98e-05	0.0001	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—AKT1—head and neck cancer	1.96e-05	9.9e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—AKT1—head and neck cancer	1.93e-05	9.74e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PTGS2—head and neck cancer	1.78e-05	8.98e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—AKT1—head and neck cancer	1.75e-05	8.86e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CA—head and neck cancer	1.67e-05	8.45e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PTEN—head and neck cancer	1.55e-05	7.83e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—AKT1—head and neck cancer	1.37e-05	6.91e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CA—head and neck cancer	1.09e-05	5.53e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—AKT1—head and neck cancer	8.93e-06	4.52e-05	CbGpPWpGaD
